Evidence map›Paper›PMID 42515563›Full record

ArticleViruses2026

The Natural Killer Cell Landscape in the Natural History of Hantavirus Cardiopulmonary Syndrome in a Chilean Cohort.

Juan Hormazabal, Natalia González, Fernanda Silva-Fuentes, Cecilia Poli, Analía Cuiza, Nicole Le Corre, Marcela Ferres, René López, Jerónimo Graf, Maria Luisa Rioseco and 7 more

Abstract read
In one paragraph

Article in Viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Juan HormazabalPrograma Hantavirus & Zoonosis, Instituto de Ciencias e Innovación en Medicina (ICIM), Facultad de Medicina, Clínica Alemana Universidad del Desarrollo, Av. La Plaza 680, Las Condes, Santiago 7500000, Chile.
Natalia GonzálezPrograma de Inmunogenética e Inmunología Traslacional, Instituto de Ciencias e Innovación en Medicina, Facultad de Medicina, Clínica Alemana Universidad del Desarrollo, Santiago 7610658, Chile.
Fernanda Silva-FuentesPrograma Hantavirus & Zoonosis, Instituto de Ciencias e Innovación en Medicina (ICIM), Facultad de Medicina, Clínica Alemana Universidad del Desarrollo, Av. La Plaza 680, Las Condes, Santiago 7500000, Chile.
Cecilia PoliPrograma de Inmunogenética e Inmunología Traslacional, Instituto de Ciencias e Innovación en Medicina, Facultad de Medicina, Clínica Alemana Universidad del Desarrollo, Santiago 7610658, Chile.
Analía CuizaPrograma Hantavirus & Zoonosis, Instituto de Ciencias e Innovación en Medicina (ICIM), Facultad de Medicina, Clínica Alemana Universidad del Desarrollo, Av. La Plaza 680, Las Condes, Santiago 7500000, Chile.
Nicole Le CorreDepartamento de Enfermedades Infecciosas e Inmunología Pediátricas, Pontificia Universidad Católica de Chile, Marcoleta 391, Región Metropolitana, Santiago 7500000, Chile.
Marcela FerresDepartamento de Enfermedades Infecciosas e Inmunología Pediátricas, Pontificia Universidad Católica de Chile, Marcoleta 391, Región Metropolitana, Santiago 7500000, Chile.ORCID 0000-0001-9415-4657
René LópezDepartamento de Paciente Crítico, Clínica, Alemana de Santiago Av. Vitacura 5951, Vitacura, Santiago 7500000, Chile.
Jerónimo GrafDepartamento de Paciente Crítico, Clínica, Alemana de Santiago Av. Vitacura 5951, Vitacura, Santiago 7500000, Chile.
Maria Luisa RiosecoRegional de Puerto Montt, Universidad San Sebastián, Sede Patagonia, Puerto Montt 5501842, Chile.
Francisco ArancibiaPulmonology Department, Instituto Nacional del Tórax, Universidad de Chile, Santiago 8330015, Chile.ORCID 0000-0001-5429-5420
Ricardo FritzPulmonology Department, Instituto Nacional del Tórax, Universidad de Chile, Santiago 8330015, Chile.
Jose Luis PerezInstitute of Clinical Sciences, Universidad Austral de Chile, Valdivia 5090000, Chile.
Leonila FerreiraHospital Regional Guillermo Grant Benavente, Concepción 4070038, Chile.
Mario CalvoHospital Regional de Valdivia, Valdivia, Chile.ORCID 0000-0002-1796-2236
Pablo VialPrograma Hantavirus & Zoonosis, Instituto de Ciencias e Innovación en Medicina (ICIM), Facultad de Medicina, Clínica Alemana Universidad del Desarrollo, Av. La Plaza 680, Las Condes, Santiago 7500000, Chile.ORCID 0000-0002-4135-0416
Cecilia VialPrograma Hantavirus & Zoonosis, Instituto de Ciencias e Innovación en Medicina (ICIM), Facultad de Medicina, Clínica Alemana Universidad del Desarrollo, Av. La Plaza 680, Las Condes, Santiago 7500000, Chile.ORCID 0000-0002-0399-6144

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hantavirus cardiopulmonary syndrome (HCPS) caused by Andes Orthohantavirus (ANDV) carries case-fatality rates up to 40%; however, the innate immune determinants of disease severity remain poorly defined. Natural killer (NK) cells are central mediators of early antiviral immunity, but their landscape during the earliest phase of ANDV infection has not been characterized. Using multiparameter flow cytometry and unsupervised UMAP-based clustering in PBMCs from 13 HCPS patients stratified by severity and nine healthy donors, we show that severe HCPS is characterized by a coordinated disruption of the CD56dim NK cell compartment, encompassing reduced subset frequencies, specific reduction in the terminally differentiated NKG2C+CD57+ adaptive-like pool, and intrinsic impairment of IFN-γ production and degranulation, deficits that were absent in mild patients and persisted in part beyond clinical recovery. Furthermore, CD56dimCD16+ NK cell frequencies correlated negatively with viral load across all acute patients, independent of clinical severity. These findings establish severe HCPS not merely as a state of NK cell depletion, but as one of selective functional impairment of the most cytotoxically competent NK cell population during the critical early acute phase of ANDV infection.

Indexed as

Hantavirus InfectionsHantavirus Pulmonary SyndromeKiller Cells, NaturalOrthohantavirusAdultCD56 AntigenChileCohort StudiesFemaleFlow CytometryHumansImmunity, InnateInterferon-gammaMaleMiddle AgedViral LoadCD56 AntigenInterferon-gammaAndes virusCD56dimdisease severityflow cytometryHCPS severityinnate immunityNK cell dysfunctionNK cell phenotypeOrthohantavirus andesenseviral immunology

Identifiers

PMID42515563
PMCPMC13431568

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.